Free tool
FAERS Monitor: Sprix
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022382 or its brand name (Sprix, Ketorolac Tromethamine). Reports on generic versions are filed under their own applications.
Reports
4,851
Serious
2,626
54% of reports
Hospitalization
1,312
Death reported
263
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective524
- drug hypersensitivity301
- nausea272
- headache263
- pain250
- dyspnoea231
- fatigue226
- treatment failure205
- off label use202
- vomiting176
- diarrhoea156
- product dose omission issue148
- dizziness135
- eye irritation128
- eye pain128
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 43 |
| 2005 | 70 |
| 2006 | 69 |
| 2007 | 64 |
| 2008 | 83 |
| 2009 | 98 |
| 2010 | 99 |
| 2011 | 166 |
| 2012 | 201 |
| 2013 | 63 |
| 2014 | 83 |
| 2015 | 109 |
| 2016 | 431 |
| 2017 | 284 |
| 2018 | 262 |
| 2019 | 369 |
| 2020 | 504 |
| 2021 | 239 |
| 2022 | 310 |
| 2023 | 372 |
| 2024 | 345 |
| 2025 | 346 |
| 2026 | 241 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,308 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 205 | 10.8 | 9.4 | 1,806 |
| eye painSignal | 128 | 9.9 | 8.3 | 1,010 |
| eye irritationSignal | 128 | 9.7 | 8.1 | 986 |
| drug hypersensitivitySignal | 301 | 6.8 | 6.1 | 1,481 |
| product dose omission issueSignal | 148 | 2.2 | 1.9 | 95 |
| headache | 263 | 1.8 | 1.6 | 99 |
| dyspnoea | 231 | 1.8 | 1.6 | 79 |
| pain | 250 | 1.8 | 1.6 | 85 |
| drug ineffective | 524 | 1.7 | 1.6 | 169 |
| vomiting | 176 | 1.6 | 1.4 | 42 |
| nausea | 272 | 1.5 | 1.3 | 45 |
| fatigue | 226 | 1.3 | 1.1 | 12 |
| dizziness | 135 | 1.2 | 1.0 | 3 |
| diarrhoea | 156 | 1.0 | 0.9 | 0 |
| off label use | 202 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.